What is the primary role of molecular diagnostics in hematologic disorders?
Master all 26 flashcards
Role of genetic/molecular diagnostics in hematologic disorders for precise diagnosis and personalized therapy.
By mastering this deck, clinicians and students will understand how molecular and genetic testing inform accurate diagnosis, prognosis, and targeted treatment strategies in hematology, enabling personalized patient management and improved outcomes.
ℹ️ Educational Use Only: This flashcard deck is created by usersof our platform for their educational and study purposes. The content is not intended as medical advice, diagnosis, or treatment guidance. Always consult qualified healthcare professionals for medical decisions and verify information with authoritative medical sources.
Showing 20 of 26 cardsSample view
| # | Front | Back | Hint |
|---|---|---|---|
| 1 | What is the primary role of molecular diagnostics in hematologic disorders? | Molecular diagnostics identify genetic abnormalities at the DNA or RNA level to aid in accurate diagnosis, prognosis, and the development of targeted therapies in hematologic disorders. | Think of molecular diagnostics as the 'genetic blueprint' for blood diseases. |
| 2 | Which genetic mutation is most commonly associated with Chronic Myeloid Leukemia (CML)? | The BCR-ABL1 fusion gene resulting from t(9;22)(q34;q11), known as the Philadelphia chromosome. | Remember 'Ph' for Philadelphia chromosome, a hallmark of CML. |
| 3 | What is the significance of FLT3 mutations in Acute Myeloid Leukemia (AML)? | FLT3 mutations are associated with a higher risk of relapse and poorer prognosis, and they guide the use of targeted FLT3 inhibitors in therapy. | Think of FLT3 as a 'growth factor receptor' influencing leukemia cell proliferation. |
| 4 | Which genetic test is commonly used to diagnose Hemophilia A and B? | Gene sequencing of F8 (Hemophilia A) and F9 (Hemophilia B) to identify mutations or deletions. | Sequence the 'factor' genes for definitive diagnosis. |
| 5 | How does Next-Generation Sequencing (NGS) benefit hematologic diagnostics? | NGS allows rapid, comprehensive analysis of multiple gene mutations simultaneously, improving diagnostic accuracy and revealing complex genetic profiles. | Think of NGS as a 'genetic scan' that covers many mutations at once. |
| 6 | What is the role of cytogenetic testing in myelodysplastic syndromes (MDS)? | Cytogenetic analysis detects chromosomal abnormalities (e.g., del(5q), monosomy 7) that influence prognosis and treatment decisions. | Cytogenetics provides the 'chromosomal map' of MDS. |
| 7 | Which molecular marker is associated with a good prognosis in Chronic Lymphocytic Leukemia (CLL)? | Mutated IGHV gene status is associated with a more favorable prognosis compared to unmutated IGHV. | Consider IGHV mutation status as a 'prognostic marker'. |
| 8 | What is the significance of JAK2 V617F mutation in myeloproliferative neoplasms? | JAK2 V617F mutation is a driver mutation in polycythemia vera, essential thrombocythemia, and primary myelofibrosis, aiding diagnosis and targeted therapy. | Think of JAK2 V617F as the 'on switch' in these disorders. |
| 9 | How can molecular testing distinguish between different types of lymphoma? | Gene rearrangement studies (e.g., immunoglobulin or T-cell receptor gene rearrangements) help identify clonality, confirming lymphoma diagnosis and subtype classification. | Clonality indicates a monoclonal proliferation typical of lymphoma. |
| 10 | What is minimal residual disease (MRD) and how is molecular testing used to assess it? | MRD refers to small numbers of cancer cells remaining after treatment, detectable via sensitive molecular techniques like PCR or NGS, guiding prognosis and therapy adjustments. | MRD detection is like finding a needle in a haystack to prevent relapse. |
| 11 | Which genetic abnormality is characteristic of Burkitt lymphoma? | c-MYC gene translocation, most commonly t(8;14)(q24;q32). | Remember 'Myc' as the 'my' gene involved in cell growth. |
| 12 | Why is it important to perform molecular testing for TP53 mutations in hematologic malignancies? | TP53 mutations are associated with resistance to therapy and poor prognosis, influencing treatment choices and risk stratification. | TP53 is the 'guardian of the genome'; mutations suggest compromised tumor suppression. |
| 13 | What is the role of fluorescence in situ hybridization (FISH) in hematology? | FISH detects specific chromosomal translocations, deletions, or amplifications at the DNA level, aiding in diagnosis and prognosis. | FISH uses fluorescent probes as 'molecular beacons' for chromosomal abnormalities. |
| 14 | How does molecular profiling assist in personalized therapy for hematologic cancers? | It identifies actionable mutations that can be targeted with specific drugs, tailoring treatment to individual genetic profiles for better efficacy and fewer side effects. | Think of molecular profiling as a 'custom map' for targeted therapy. |
| 15 | What is the significance of detecting the PML-RARA fusion gene in hematology? | It confirms diagnosis of acute promyelocytic leukemia (APL) and guides specific treatment with all-trans retinoic acid (ATRA). | PML-RARA fusion is the 'signature' translocation in APL. |
| 16 | Which genetic abnormality is most commonly associated with multiple myeloma? | Translocation t(4;14) and deletion del(13q) are common abnormalities associated with prognosis. | Think of translocations as 'genetic rearrangements' affecting prognosis. |
| 17 | What is the purpose of using liquid biopsy in hematology? | Liquid biopsy detects circulating tumor DNA or cells in blood, allowing minimally invasive monitoring of disease and detection of mutations. | Liquid biopsy is like a 'blood test' for tumor genetics. |
| 18 | How do genetic tests influence the management of sickle cell disease? | Genetic testing confirms diagnosis, carrier status, and helps identify modifiers that influence disease severity, informing personalized management strategies. | Genetics help tailor care in sickle cell's variable presentation. |
| 19 | What is the significance of detecting the CALR mutation in myeloproliferative neoplasms? | CALR mutations are associated with essential thrombocythemia and primary myelofibrosis, especially in JAK2-negative cases, impacting diagnosis and prognosis. | CALR mutations serve as alternative drivers in MPNs. |
| 20 | In what way does genetic testing aid in distinguishing between different subtypes of acute leukemia? | Genetic testing identifies specific translocations and mutations (e.g., PML-RARA, AML1-ETO), enabling precise classification and targeted therapy selection. | Genetics define the 'molecular signature' of leukemia subtypes. |
Note: This preview shows only the first 20 cards. The complete deck contains 26 total cards. Start studying to access all flashcards.
Master all 26 flashcards
Explore other decks you might find helpful